Recombinant factor VIIa analog in the management of hemophilia with inhibitors: Results from a multicenter, randomized, controlled trial of vatreptacog alfa

S. R. Lentz, S. Ehrenforth, F. Abdul Karim, T. Matsushita, K. N. Weldingh, J. Windyga, J. N. Mahlangu, A. Weltermann, E. de Paula, M. Cerqueira, S. Zupancic-Salek, O. Katsarou, M. Economou, L. Nemes, Z. Boda, E. Santagostino, G. Tagariello, H. Hanabusa, K. Fukutake, M. TakiM. Shima, M. Gorska-Kosicka, M. Serban, T. Andreeva, A. Savic, I. Elezovic, J. Mahlangu, W. Tsay, M. Shen, A. Chuansumrit, P. Angchaisuksiri, K. Kavakli, A. Kupesiz, I. Sasmaz, B. Madan, S. Rangarajan, P. Giangrande, K. Saxena, M. Recht, C. Kempton, J. Barrett, G. Young, D. Quon, A. Stopeck, J. Lin, A. Ameri, S. Kaicker, P. Kuriakose, D. Obzut, M. Wang, I. Ortiz, A. Sori

Research output: Contribution to journalArticlepeer-review

50 Scopus citations

Fingerprint

Dive into the research topics of 'Recombinant factor VIIa analog in the management of hemophilia with inhibitors: Results from a multicenter, randomized, controlled trial of vatreptacog alfa'. Together they form a unique fingerprint.

Medicine & Life Sciences